Planned Clinical Phase I Trial to Examine the Safety of Vaccine Against Gliomas Based on Mutant IDH1 in Human Patients

“Astrocytomas and oligodendrogliomas are subtypes of a brain cancer called ‘glioma’. These incurable brain tumors arise from glial cells, a type of support cell found in the central nervous system. ‘Low-grade gliomas’, which grow comparatively slowly, spread in a diffuse manner across the brain and are very difficult to completely eliminate through surgery. In many cases, the effectiveness of treatments with chemotherapy and radiotherapy is very limited. Gliomas can develop into extremely aggressive glioblastomas.

“Low-grade gliomas have a particular feature in common: more than 70% of the cases exhibit the same gene mutation in tumor cells. An identical ‘typo’ in the DNA causes the exchange of a single, specific protein building block (amino acid) in an enzyme called isocitrate dehydrogenase 1 (IDH1). As a result, most cancer cells do not follow the original building plan for the protein; at the 132nd position in the molecule’s sequence, they insert the amino acid histidine instead of arginine…

” ‘…we might be able to use a vaccine to alert the patient’s immune system to mutant IDH1, fighting the tumor without damaging healthy cells,’ [Prof. Dr. Michael Platten at the German Consortium for Translational Cancer Research] explains.

“In collaboration with a team of physicians and scientists from Heidelberg University Hospital, DKFZ and the Universities of Mainz, Tübingen and Hamburg, Platten and his co-workers have now made the first successful step toward a vaccine that specifically targets the mutation in the tumor.

“In a clinical trial scheduled to start early next year, with the support of the German Consortium for Translational Cancer Research (DKTK), they plan to examine the safety of the vaccine against gliomas based on mutant IDH1 in human patients, for the first time.”

Editor’s note: Early next year, oncologists will begin testing a newly developed cancer vaccine in a clinical trial with volunteer patients, in the hopes that it will help treat low-grade gliomas. Cancer vaccines are a type of immunotherapy treatment; they boost a patient’s own immune system to fight cancer. The new vaccine takes advantage of a dysfunctional protein that is found in 70% of low-grade gliomas. The protein is called IDH1, and the vaccine is designed to alert the patient’s immune system to attack cells with mutant IDH1, potentially shrinking the brain tumor. So far, the vaccine has only been tested in mice, but the results were promising.


Isocitrate Dehydrogenase 1 Is a Novel Plasma Biomarker for the Diagnosis of Non–Small Cell Lung Cancer

We previously showed that isocitrate dehydrogenase 1 (IDH1) is significantly increased in NSCLC tumors. This study aimed to examine the plasma levels of IDH1 in a large patient population to evaluate its effectiveness in NSCLC diagnosis.

IDH1 can be used as a plasma biomarker for the diagnosis of NSCLCs, particularly lung adenocarcinoma, with relatively high sensitivity and specificity.